Smith & Nephew SNATS, Inc.
SNN Healthcare Medical Devices
Smith & Nephew SNATS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, up 6.09% from fiscal 2024.
Follow SNN
Alert me
Smith & Nephew SNATS, Inc. (SNN) P/B ratio
As of 5 November 2026, Smith & Nephew SNATS, Inc. (SNN) trades at a P/B ratio of 2.8×. Over the past ten years it has ranged from 1.8× (September 2022) to 4.5× (February 2020); the current reading is higher than 36% of that period. That is above the Medical Devices industry median of 2.5× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 2.8× | 32.88% |
| FY2024 | 2.1× | (9.29%) |
| FY2023 | 2.3× | (0.82%) |
| FY2022 | 2.3× | (16.54%) |
| FY2021 | 2.8× | (22.16%) |
| FY2020 | 3.6× | (14.57%) |
| FY2019 | 4.2× | 21.92% |
| FY2018 | 3.4× | 2.05% |
| FY2017 | 3.4× | (0.82%) |
| FY2016 | 3.4× | (15.59%) |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Jun 2023 | 2.7× | 18.76% |
| Dec 2022 | 2.3× | (0.41%) |
| Jun 2022 | 2.3× | (16.96%) |
| Dec 2021 | 2.7× | (23.52%) |
| 6 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| BIO Bio-Rad Laboratories, Inc. compare | 1.3× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 1.3× |
| GMED Globus Medical, Inc. compare | 2.3× |
| SNN Smith & Nephew SNATS, Inc. | 2.8× |
| BRKR Bruker Corporation compare | 3.7× |
| PODD Insulet Corporation compare | 7.6× |
| PEN Penumbra, Inc. compare | 8.0× |
| TXG 10x Genomics compare | 9.2× |
| GKOS Glaukos Corporation compare | 18.1× |
| Medical Devices industry median | 2.5× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on SNN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement